US Poison Centers See Liver Injury Call Surge

United States poison centers documented a substantial increase in calls related to liver injury, experiencing a nearly fourfold rise from 2000 to 2024. Acetaminophen, widely known by its brand name Tylenol, was identified as the most frequently implicated substance in these cases. This trend was detailed in a report published in Clinical Gastroenterology and Hepatology, highlighting a significant public health concern regarding drug-induced liver injury (DILI).

The data, compiled from the National Poison Data System, revealed that calls concerning liver injury escalated from 53,000 in 2000 to over 130,000 in 2024. Acetaminophen, a common over-the-counter pain reliever and fever reducer, was responsible for a significant portion of these incidents. The report did not specify the exact percentage of acetaminophen-related calls but emphasized its leading role. This surge underscores the critical need for public awareness regarding the safe use of acetaminophen, particularly concerning dosage limits and potential interactions with other substances or underlying health conditions.

Beyond acetaminophen, the study also noted other substances contributing to liver injury calls, though none reached the prevalence of Tylenol. These included various prescription medications, herbal supplements, and illicit drugs. The researchers pointed out that the rise in calls may be attributed to several factors, including increased public awareness of DILI, broader access to healthcare services that report such incidents, and potentially an actual increase in liver injury cases due to factors like polypharmacy and the growing prevalence of chronic diseases that can be exacerbated by liver damage.

Furthermore, the study touched upon the growing prevalence of Inflammatory Bowel Disease (IBD) in the U.S., with rates continuing to climb. While not directly linked to the liver injury calls in the primary analysis, the co-occurrence of chronic conditions like IBD and the potential for DILI presents complex challenges for healthcare providers. Managing patients with IBD often involves multiple medications, increasing the risk of drug interactions and adverse events, including liver toxicity. The report also briefly mentioned the use of comedy therapy as a potential adjunct in managing patients awaiting liver transplants, suggesting a holistic approach to patient care that extends beyond pharmacological interventions.

The findings from the poison center data serve as a crucial indicator for public health initiatives aimed at preventing DILI. Recommendations include enhanced patient education on safe medication use, stricter regulatory oversight for certain supplements, and continued research into the mechanisms and risk factors associated with drug-induced liver damage. The consistent increase in calls over two decades signals an ongoing challenge that requires sustained attention from healthcare professionals, policymakers, and the public to mitigate the risks associated with common medications like acetaminophen.